Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer
Nicolas Guibert(Université Fédérale de Toulouse Midi-Pyrénées), Julien Mazières(Université Toulouse III - Paul Sabatier)
Cited by 102
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2020|1.1k
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
|Nature Medicine|2022|637
False-Positive Plasma Genotyping Due to Clonal Hematopoiesis
|Clinical Cancer Research|2018|445
Wnt2 as a new therapeutic target in malignant pleural mesothelioma
|International Journal of Cancer|2005|69